Santhera Pharmaceuticals (SIX: SANN) announces that its shareholders have approved all proposals by the Board of Directors at the Annual General Meeting (AGM) held today at the Company's domicile in Pratteln, Switzerland.

In total, 8,578,380 shares equaling 27.4% of the Company's share capital were represented.

'I am very grateful to Santhera's shareholders for their steadfast support and consent at today's AGM,' said Elmar Schnee, Chairman of the Board of Directors. 'With the exciting results from the VISION DMD study with vamorolone in Duchenne muscular dystrophy (DMD), our Company is in the starting blocks to embark on the growth path. Our shareholders' approval provides Santhera with flexibility to a range of alternative financing, including non-dilutive options, while ensuring the Company is adequately capitalized as we prepare for the launch of vamorolone. In doing so, new funds will support our efforts in expanding our organization, especially in the US, and initiate pre-commercialization activities.'

About Santhera

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. Santhera has an exclusive license for all indications worldwide to vamorolone, a first-in-class dissociative steroid with novel mode of action, which was investigated in a pivotal study in patients with DMD as an alternative to standard corticosteroids. The clinical stage pipeline also includes lonodelestat (POL6014) to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases as well as an exploratory gene therapy approach targeting congenital muscular dystrophies. Santhera out-licensed rights to its first approved product, Raxone (idebenone), outside North America and France for the treatment of Leber's hereditary optic neuropathy (LHON) to Chiesi Group.

Contact:

Tel: +41 79 875 27 80

Email: eva.kalias@santhera.com

(C) 2021 Electronic News Publishing, source ENP Newswire